Skip to main content

Table 1 Clinical characteristics of 5 patients with ovarian fibrosarcoma

From: Ovarian fibrosarcoma: A single-institution experience and a review of the literature

NO.

Case 1

Case 2

Case 3

Case 4

Case 5

Age, (year)

57

41

76

76

51

Menopausal status

Yes

No

Yes

Yes

Yes

Gravidity/ Parity

1/1

2/1

4/4

1/1

1/1

Clinical presentations

Mass

Mass

Mass, pain, fever

Mass, pain

Mass, pain, fever

Ultrasound

Thickly capsulated, 9.6*8.2*5.2 cm, irregular, left; septa inside; small amount of blood flow signal; liquid depth 4.6 cm.

Heterogeneous, left, clear boundary, 6.1*5.5*4.6 cm.

Irregular, cystic, 10*8.6 cm, unclear boundary, uneven in thickness.

Heterogeneous, irregular, hypoechoic, unclear boundary, 11.4*13.5*8.6 cm; punctiform blood flow signals; liquid depth 1.6 cm.

Solid, clear boundaries, 7.3*5.9*6.5 cm, abundant arteriovenous blood flow signals.

Size of mass, cm

8*10

7*6

10

20

10*15

Side of mass

Right

Left

Left

Left

Left

CA 125, U/ml

(normal range ≤ 35 U/ml)

9.9

40.4

15.5

593.3

88.8

Surgery

TAH + BSO

Ovarian cystectomy + sampling of right ovary.

Secondary cytoreductive surgery

Left adnexectomy

TAH + BSO;

Partial removal of pelvic mass

FIGO Stage

IC

IA

-

IIIC

II

Intraoperative pathology

NA

Left ovarian follicular fibroma

NA

NA

Sexostromal tumor, not excluding malignant tumor.

Final

pathology

Well-differentiated fibrosarcoma

Fibrosarcoma

Fibrosarcoma

Fibrosarcoma

Fibrosarcoma

Mitotic counts/ HPF

-

> 10

-

> 10

> 40

Ki-67

-

5%

10%

40%

70%

Immunohistochemistry

Vimentin (+), SMA (+), PR (±), ER (-), CD10 (-), Caldeson (-), Melan (-), α-inhibin (-).

AE1/AE3 (-), Calretinin (-), Ki-67 (index 5%), p53 (-), α-inhibin (-).

Melan-A (+), Vimentin (+), AE1/AE3 (+/-), CD99 (-), Calretinin (-), α-inhibin (-), Ki-67 (index10%).

CA125 (-), CD10 (partial+), Desmin (-), Ki-67 (index40%), SMA (+), S-100 (-), Vimentin (+), p53 (-), α-inhibin(-).

CD31(+), Ki-67(+ 70%), SMA(+), AE1/AE3(-), CD34(-), CD117(-), ER(-), PR(-), Desmin(-).

Adjuvant therapy

PVB*2

No

No

No

PEI; TC

Relapse

No

No

No

Yes

Yes

OS, y

> 15

> 7

> 6

< 1

< 1

  1. Abbreviations: y year, cm centimeter, CA-125 cancer antigen 125, FIGO Federation International Gynecology Obstetrics, PVB, Cisplatin + Vincristine + Bleomycin, PEI Cisplatin + Epirubicin + Ifosfamide, TC Taxol + Carboplatin, OS overall survival